Business Context and Reporting Period
This Form 8-K/A (Amendment No. 1) was filed by Immunic, Inc. (formerly Vital Therapies, Inc.) on June 21, 2019. The filing amends an original report to provide historical and pro-forma financial information regarding the acquisition of Immunic AG (Former Immunic). The transaction closed on April 12, 2019, resulting in Former Immunic becoming a wholly-owned subsidiary and the registrant changing its name to Immunic, Inc.
Key Financial Metrics
The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it references the following exhibits where this data is located:
- Historical Financials: Audited statements for Former Immunic for years ended December 31, 2018 and 2017 (Exhibit 99.2); Unaudited interim statements for the three months ended March 31, 2019 and 2018 (Exhibit 99.3).
- Pro Forma Data: Unaudited pro forma condensed combined balance sheet as of March 31, 2019, and statements of operations for the three months ended March 31, 2019, and the year ended December 31, 2018 (Exhibit 99.4).
Material Changes
The primary material change reported is the completion of the Exchange Agreement dated January 6, 2019. Key aspects include:
- Shareholders of Former Immunic exchanged all outstanding shares for shares of the Company's common stock.
- Former Immunic became a wholly-owned subsidiary of the Company.
- The Company changed its name from Vital Therapies, Inc. to Immunic, Inc.
Guidance, Outlook, and Risks
The filing includes a press release dated June 21, 2019 (Exhibit 99.1), which is incorporated by reference, but the text of the press release is not provided in the input. Consequently, specific management commentary, future guidance, or detailed risk factors are not available in this summary. The filing notes that the Company is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.
Investor Verification Checklist
- Review Exhibit 99.2 and 99.3 for the actual financial performance of Former Immunic prior to the acquisition.
- Analyze Exhibit 99.4 for pro forma financial results to understand the combined entity's financial position as of March 31, 2019.
- Read Exhibit 99.1 (Press Release) for specific details on the strategic rationale and any forward-looking statements made on June 21, 2019.
- Verify the terms of the Exchange Agreement to understand the share exchange ratio and any contingent consideration.